Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK

Cherubini Antonella Trieste (Trieste) РSc Cardiovascolare Asugi, Azienda Sanitaria Universitaria Giuliano Isontina | Tollardo Marika Trieste (Trieste) РUniversità Degli Studi | Palcic Stefano Trieste (Trieste) РSc Farmacia Ospedaliera E Territoriale Area Giuliana, Asugi, | Scagnetto Arjuna Trieste (Trieste) РSc Cardiovascolare Asugi, Azienda Sanitaria Universitaria Giuliano Isontina | Russo Giulia Trieste (Trieste) РSc Cardiovascolare Asugi, Azienda Sanitaria Universitaria Giuliano Isontina | Capelletto Chiara Trieste (Trieste) РSc Cardiovascolare Asugi, Azienda Sanitaria Universitaria Giuliano Isontina | Bollini Marina Trieste (Trieste) РSc Cardiovascolare Asugi, Azienda Sanitaria Universitaria Giuliano Isontina | Di Lenarda Andrea Trieste (Trieste) РSc Cardiovascolare Asugi, Azienda Sanitaria Universitaria Giuliano Isontina

Background: Guidelines of treatment of hypercholesterolemia in patients at very high cardiovascular (CV) risk have progressively lowered the target LDL-cholesterol (LDL-C). In real life LDL-C targets are difficult to reach.

Aim of this study was to evaluate the achievement of LDL-C targets and the prescription of lipid-lowering therapy (LLT) in a large cohort of outpatients at very high CV risk.

Methods:  we considered 11350 patients at very high CV risk, mean age 70 years evaluated in Our Center from 2017 to 2020. The study population was divided in 3 groups according to the presence of one or more very high risk CV score components. For each group lipid-lowering therapy, LDL-C goal and prognosis were assessed.

Results: The very high CV risk population was composed maily by patients with coronary artery disease (CAD). We found an increse of LLT after  the index cardiologic visit (from 50,5 to 75,8%) and high-efficacy (HE) LLT from 22% to 27,9%.  Consequently we found an increase in the achievement of LDL-C target <55 mg/dl (1.4 mmol/l): from 3,2% to 8,3% 6 months after the visit. In the group with more CV risk components the LLT and HE LLT were more prescribed, the LDL-C target was more reached and the mortality rate were higher (22,3% vs 8,4%  in patients with only one CV risk component).

Conclusions: in the very high CV risk population the target of LDL-C is rarely reached. We identificated patients with more CV risk components with worse prognosis and need of HE LLT.